Inicio>>Signaling Pathways>> DNA Damage/DNA Repair>> DNA Methyltransferase>>(R)-GSK-3685032

(R)-GSK-3685032

Catalog No.GC64210

(R)-GSK-3685032 es el enantiÓmero R de GSK-3685032. GSK-3685032 es un inhibidor selectivo de DNMT1 reversible no dependiente del tiempo, no covalente, primero en su clase, con una IC50 de 0,036 μM. GSK-3685032 induce una fuerte pérdida de metilaciÓn del ADN, activaciÓn transcripcional e inhibiciÓn del crecimiento de células cancerosas.

Products are for research use only. Not for human use. We do not sell to patients.

(R)-GSK-3685032 Chemical Structure

Cas No.: 2170140-50-6

Tamaño Precio Disponibilidad Cantidad
5 mg
450,00 $
Disponible
10 mg
765,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

(R)-GSK-3685032 is the R-enantiomer of GSK-3685032. GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition[1][2].

[1]. Adams, Nicholas David, et al. Substituted pyridines as inhibitors of DNMT1 and their preparation. WO2017216727A1.
[2]. Pappalardi MB, et al. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer. 2021;2(10):1002-1017.

Reseñas

Review for (R)-GSK-3685032

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (R)-GSK-3685032

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.